• Le 21 janvier 2020
    Campus Centre Loire

" Control of TH17 cells and associated cytokines in IMIDs and cancer "

Dr Samuel HUBER
University medical centre Hamburg – Eppendorf, Department of internal medicine, Hamburg

My background is in the field of Gastroenterology and Immunobiology. During my M.D thesis, I focused on the role of
TGF-beta1 for the emergence and function of Foxp3+ TREG in vivo (Huber et al. JI 2004). I then obtained the board
certification for Medicine in 2006 and started my residency at the I. Department of Medicine (Gastroenterology),
University Medical Center Hamburg-Eppendorf (chairman: Prof. A.W. Lohse). In addition to my medical training in
the clinic, I continued my research on regulatory T cells in the lab of Prof. Dr. Christoph Schramm focusing on the role
of other TGF-beta family members (Huber et al. JI 2009; Lueth, Huber et al. JCI 2008). From 2008-2012 I did my
postdoctoral training at Richard A. Flavell’s lab at the Department of Immunobiology, School of Medicine, Yale
University. The main focus of my postdoc was to identify ways to control TH17 cells in vivo, especially in the intestine
(Huber et al. Immunity 2011; Esplugues, Huber et al. Nature 2011, Huber et al. Nature 2012). After my postdoctoral
training, I completed my medical fellowship, I obtained the board certification for Internal Medicine at the end of
2015, and in parallel I established my own lab at the I. Department of Medicine, University Medical Center Hamburg-
Eppendorf. I became Head of the Section of Molecular Immunology and Gastroenterology in 2013. Since 2016 I have
also been leading the outpatient unit for IBD patients. The main focus of my lab is to study the mechanisms
controlling homeostasis in the intestine in mice and humans using mouse models and analysing human samples
(Gagliani et al. Nature 2015; Pelczar et al. Science 2016; Brockmann et al. JI 2017; Brockmann et al. Nat Commun
2018). Our long term aim is to identify new therapeutic targets for the treatment of inflammatory bowel disease and
colorectal cancer.

Invité par le Pr Régis Josien